Abstract
Acute myelogenous leukemia (AML) is a difficult disease to treat. Novel treatment strategies, including molecular targeted therapy, are currently being explored. The c-kit receptor represents a potential therapeutic target for AML. The receptor is expressed on more than 10% of blasts in 64% of de novo AMLs and 95% of relapsed AMLs. C-kit mediates proliferation and anti-apoptotic effects in AML. This review will discuss the biology of c-kit in normal and malignant hematopoiesis, and the recent clinical trials targeting c-kit in AML.
MeSH terms
-
Acute Disease
-
Angiogenesis Inhibitors / pharmacology
-
Angiogenesis Inhibitors / therapeutic use
-
Animals
-
Antineoplastic Agents / pharmacology*
-
Antineoplastic Agents / therapeutic use
-
Benzamides
-
Cell Line, Tumor
-
Clinical Trials as Topic
-
Hematopoiesis
-
Humans
-
Imatinib Mesylate
-
Indoles / pharmacology
-
Indoles / therapeutic use
-
Leukemia, Myeloid / drug therapy*
-
Leukemia, Myeloid / genetics
-
Mice
-
Oxindoles
-
Piperazines / therapeutic use
-
Propionates
-
Protein Kinase Inhibitors / pharmacology*
-
Protein Kinase Inhibitors / therapeutic use
-
Protein Processing, Post-Translational / drug effects
-
Proto-Oncogene Proteins c-kit / chemistry
-
Proto-Oncogene Proteins c-kit / drug effects*
-
Proto-Oncogene Proteins c-kit / genetics
-
Proto-Oncogene Proteins c-kit / physiology
-
Pyrimidines / therapeutic use
-
Pyrroles / pharmacology
-
Pyrroles / therapeutic use
-
Stem Cell Factor / physiology*
-
Stem Cell Factor / therapeutic use
Substances
-
Angiogenesis Inhibitors
-
Antineoplastic Agents
-
Benzamides
-
Indoles
-
Oxindoles
-
Piperazines
-
Propionates
-
Protein Kinase Inhibitors
-
Pyrimidines
-
Pyrroles
-
Stem Cell Factor
-
Semaxinib
-
Imatinib Mesylate
-
orantinib
-
Proto-Oncogene Proteins c-kit